OTCMKTS:CMPD CompuMed (CMPD) Stock Price, News & Analysis $3.06 0.00 (0.00%) As of 05/7/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsShort InterestBuy This Stock About CompuMed Stock (OTCMKTS:CMPD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CompuMed alerts:Sign Up Key Stats Today's Range$3.06▼$3.0650-Day Range$2.90▼$3.8052-Week Range$1.61▼$4.70VolumeN/AAverage Volume2,038 shsMarket Capitalization$4.06 millionP/E Ratio18.01Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCompuMed, Inc., an enterprise telemedicine solutions company, provides clinical care services for patients and medical facilities. It offers telecardiology and teleradiology services that provide real-time access to U.S. Board-Certified specialists through cloud-based technology and integrated medical devices to medical facilities worldwide. The company also provides enterprise telemedicine solutions; a suite of telecardiology services and diagnostic exam interpretations for pediatric and adult patients, including electrocardiogram (ECG) devices, echocardiogram, ECG, vascular, holter, nuclear, and video consults; and reading, transcription, reporting, storage, and video consultations in the areas of Vscan, X-ray, ultrasound, mammography, computed tomography, magnetic resonance imaging, and radiologist video consults. It also offers OsteoGram software that works in combination with standard or digital X-ray equipment to support osteoporosis screening, diagnosis, and therapy monitoring. In addition, the company provides mobile ECG and ultrasound solutions that provide patients with immediate access to its board-certified specialists; and medical devices. It serves organ procurement organizations, rural healthcare, and correctional healthcare industries. CompuMed, Inc. was founded in 1973 and is headquartered in Los Angeles, California.Read More… CompuMed Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks21st Percentile Overall ScoreCMPD MarketRank™: CompuMed scored higher than 21% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for CompuMed. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of CompuMed is 18.01, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 22.18.Price to Earnings Ratio vs. SectorThe P/E ratio of CompuMed is 18.01, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 24.94.Price to Book Value per Share RatioCompuMed has a P/B Ratio of 1.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CompuMed's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.48% of the float of CompuMed has been sold short.Short Interest Ratio / Days to CoverCompuMed has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CompuMed has recently decreased by 1.96%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCompuMed does not currently pay a dividend.Dividend GrowthCompuMed does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.48% of the float of CompuMed has been sold short.Short Interest Ratio / Days to CoverCompuMed has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CompuMed has recently decreased by 1.96%, indicating that investor sentiment is improving. News and Social Media0.9 / 5News Sentiment-0.44 News SentimentCompuMed has a news sentiment score of -0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for CompuMed this week, compared to 0 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CompuMed insiders have not sold or bought any company stock.Percentage Held by Insiders22.00% of the stock of CompuMed is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about CompuMed's insider trading history. Receive CMPD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CompuMed and its competitors with MarketBeat's FREE daily newsletter. Email Address CMPD Stock News HeadlinesCMPD arrests juvenile for handgun, marijuana possessionMay 7 at 12:12 AM | yahoo.comCompuMed, Inc. (CMPD) Latest Stock News & Headlines - Yahoo FinanceMay 4, 2025 | finance.yahoo.comHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.May 9, 2025 | Brownstone Research (Ad)CMPD investigating after deadly shooting in Uptown CharlotteNovember 6, 2024 | yahoo.comCMPD to discuss theft ring caseAugust 24, 2024 | yahoo.comCompumed Inc.May 23, 2024 | wsj.comCompuMed, Inc.: CompuMed, FireStarter Collaborate to Further Shared Vision of Saving More Lives through Organ Donation and TransplantationMay 1, 2024 | finanznachrichten.deCompuMed, Inc. (CMPD) Stock Price, News, Quote & History - Yahoo FinanceApril 24, 2024 | finance.yahoo.comSee More Headlines CMPD Stock Analysis - Frequently Asked Questions How have CMPD shares performed this year? CompuMed's stock was trading at $3.81 on January 1st, 2025. Since then, CMPD stock has decreased by 19.6% and is now trading at $3.0625. View the best growth stocks for 2025 here. How were CompuMed's earnings last quarter? CompuMed, Inc. (OTCMKTS:CMPD) announced its quarterly earnings results on Monday, December, 16th. The company reported $0.02 earnings per share (EPS) for the quarter. CompuMed had a net margin of 3.44% and a trailing twelve-month return on equity of 6.96%. When did CompuMed's stock split? CompuMed's stock reverse split before market open on Saturday, May 21st 2022. The 1-25 reverse split was announced on Saturday, May 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Saturday, May 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of CompuMed? Shares of CMPD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CompuMed own? Based on aggregate information from My MarketBeat watchlists, some other companies that CompuMed investors own include Yamana Gold (AUY) and Agnico Eagle Mines (AEM). Company Calendar Last Earnings12/16/2024Today5/08/2025Next Earnings (Estimated)5/12/2025Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Data processing & preparation Sub-IndustryBusiness Services Current SymbolOTCMKTS:CMPD CIKN/A Webwww.compumed.net Phone(310) 258-5000Fax310-645-5880Employees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.17 Trailing P/E Ratio18.01 Forward P/E RatioN/A P/E GrowthN/ANet Income$190,000.00 Net Margins3.44% Pretax Margin2.29% Return on Equity6.96% Return on Assets5.06% Debt Debt-to-Equity Ratio0.05 Current Ratio2.49 Quick Ratio2.15 Sales & Book Value Annual Sales$6.22 million Price / Sales0.65 Cash Flow$0.42 per share Price / Cash Flow7.24 Book Value$2.42 per share Price / Book1.27Miscellaneous Outstanding Shares1,326,000Free Float1,034,000Market Cap$4.06 million OptionableNot Optionable Beta-0.02 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (OTCMKTS:CMPD) was last updated on 5/9/2025 by MarketBeat.com Staff From Our PartnersElon Warns “America Is Broke”. Trump’s Plan Inside.Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CompuMed, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CompuMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.